See more
Medical Affairs
1 ago, 2025
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the primary curative approach for patients with high-risk myeloid neoplasms (HR-MN), such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Despite advances in transplant techniques, post-HSCT relapse continues to be the leading cause of mortality. In this context, maintenance therapies have emerged as promising strategies to prolong remission. This study evaluated the use of lo
4min
The phase 3 ECHO trial evaluated the efficacy and safety of adding the second-generation BTK inhibitor acalabrutinib to standard bendamustine-rituximab (BR) in patients with previously untreated mantle cell lymphoma (MCL). A total of 598 patients were randomized to receive either acalabrutinib + BR (A+BR) or placebo + BR (P+BR), followed by maintenance with acalabrutinib or placebo.After a median follow-up of 61.6 months, the A+BR arm d
Primary aldosteronism (PA) is now recognized as the most common cause of endocrine hypertension, with prevalence estimates ranging from 5% to 10% in hypertensive populations. In their comprehensive update, Rossi and colleagues reaffirm the importance of early and accurate diagnosis, emphasizing that untreated or underdiagnosed PA leads to higher cardiovascular and renal risk than essential hypertension.The authors propose a practical al
3min
Show more
